X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SANOFI INDIA SUVEN LIFE/
SANOFI INDIA
 
P/E (TTM) x 19.0 39.9 47.7% View Chart
P/BV x 4.2 8.6 48.3% View Chart
Dividend Yield % 0.5 1.0 52.4%  

Financials

 SUVEN LIFE   SANOFI INDIA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-18
SANOFI INDIA
Dec-16
SUVEN LIFE/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2514,560 5.5%   
Low Rs1554,400 3.5%   
Sales per share (Unadj.) Rs49.11,028.5 4.8%  
Earnings per share (Unadj.) Rs9.7129.0 7.5%  
Cash flow per share (Unadj.) Rs11.4186.0 6.1%  
Dividends per share (Unadj.) Rs1.5068.00 2.2%  
Dividend yield (eoy) %0.71.5 48.7%  
Book value per share (Unadj.) Rs60.3753.6 8.0%  
Shares outstanding (eoy) m127.2823.03 552.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.14.4 94.8%   
Avg P/E ratio x20.934.7 60.1%  
P/CF ratio (eoy) x17.824.1 73.9%  
Price / Book Value ratio x3.45.9 56.6%  
Dividend payout %15.452.7 29.3%   
Avg Mkt Cap Rs m25,825103,174 25.0%   
No. of employees `0001.13.6 29.6%   
Total wages/salary Rs m6133,592 17.1%   
Avg. sales/employee Rs Th5,832.66,537.7 89.2%   
Avg. wages/employee Rs Th571.5991.4 57.6%   
Avg. net profit/employee Rs Th1,153.8819.8 140.7%   
INCOME DATA
Net Sales Rs m6,25323,686 26.4%  
Other income Rs m233708 32.9%   
Total revenues Rs m6,48524,394 26.6%   
Gross profit Rs m1,9825,281 37.5%  
Depreciation Rs m2131,313 16.2%   
Interest Rs m4615 308.7%   
Profit before tax Rs m1,9554,661 41.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7181,691 42.5%   
Profit after tax Rs m1,2372,970 41.6%  
Gross profit margin %31.722.3 142.2%  
Effective tax rate %36.736.3 101.3%   
Net profit margin %19.812.5 157.8%  
BALANCE SHEET DATA
Current assets Rs m5,62215,673 35.9%   
Current liabilities Rs m1,1686,678 17.5%   
Net working cap to sales %71.238.0 187.6%  
Current ratio x4.82.3 205.2%  
Inventory Days Days8176 107.1%  
Debtors Days Days3622 161.0%  
Net fixed assets Rs m3,3258,098 41.1%   
Share capital Rs m127230 55.3%   
"Free" reserves Rs m7,54717,088 44.2%   
Net worth Rs m7,67417,356 44.2%   
Long term debt Rs m140-   
Total assets Rs m9,13525,400 36.0%  
Interest coverage x43.2311.7 13.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.9 73.4%   
Return on assets %14.011.8 119.5%  
Return on equity %16.117.1 94.2%  
Return on capital %26.026.9 96.6%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m5,0667,145 70.9%   
Fx outflow Rs m2,0016,846 29.2%   
Net fx Rs m3,065299 1,025.1%   
CASH FLOW
From Operations Rs m6993,226 21.7%  
From Investments Rs m-6-1,555 0.4%  
From Financial Activity Rs m-577-1,818 31.7%  
Net Cashflow Rs m116-147 -79.1%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.0 14.4 -  
FIIs % 0.0 14.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.5 347.6%  
Shareholders   37,287 15,184 245.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  BIOCON LTD  J.B.CHEMICALS  

Compare SUVEN LIFE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Sep 21, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE - PLETHICO PHARMA COMPARISON

COMPARE SUVEN LIFE WITH

MARKET STATS